Hematology

Key opinion leaders discuss data from the MURANO trial on a fixed-duration therapy for relapsed/refractory chronic lymphocytic leukemia.

A hematology expert describes data from clinical trials on venetoclax-based therapies for chronic lymphocytic leukemia.

Drs Katie Tobon and Javier Pinilla-Ibarz explore the role of prognostic molecular testing in chronic lymphocytic leukemia and comment on challenges seen with referral patients that come from community practices.

Patients receiving brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in the frontline setting had a 41% reduction in the risk of death.

The trial studied 3 dosing regimens of asparaginase erwinia chrysanthemi (recombinant)-rywn, with cohort 1a receiving 25 mg/m2administered Monday and Wednesday and 50 mg/m2administered on Friday.

Granulomatosis is among a group of blood vessel disorders called vasculitis.

In a clinical trial, the median annualized bleeding rates for all bleeds was reduced from a historical median of 5 to an on-study median of 2.3, which is a 54.7% reduction.

Dr Anthony Perissinotti explains the new formulation of acalabrutinib for chronic lymphocytic leukemia presented at ASH 2021.

Dr Kirollos Hanna details clinical trial data on the use of zanubrutinib in treating chronic lymphocytic leukemia.

Lisa Nodzon, PhD, ARNP, AOCNP, and Javier Pinilla-Ibarz, MD, PhD, review challenges in CLL therapy, including cost barriers.

Further, the 1-year update suggests that Cohort 6 toxicity management strategy can improve certain AEs without compromising the activity of axicabtagene ciloleucel.

Umbralisib (Ukoniq) is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and relapsed or refractory follicular lymphoma.

The research team conducted a systematic review to collect the available published evidence on the topic and then combined the results using a process called meta-analysis.

Javier Pinilla-Ibarz, MD, PhD; Lisa Nodzon, PhD, ARNP, AOCNP; and Katie Tobon, PharmD, BCOP, describe the incidence of CLL and discuss factors that may increase the risk of disease.

Kovaltry temporarily replaces the missing clotting Factor VIII in patients with hemophilia A.

IMX-110 is a tissue-specific therapeutic designed to accumulate at intended therapeutic sites at 3 to 5 times the rate of conventional therapeutics.

The observed increase in patient age at the time of relapse makes the findings even more impressive because longer survival is typically associated with younger age at the time of relapse.

C-CAR039 showed positive efficacy and safety data in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Giant cell arteritis frequently causes headaches, scalp tenderness, jaw pain and vision problems.

Emicizumab (Hemlibra, Roche) is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A with or without factor VIII inhibitors.

The submission is supported by data from MajesTEC-1, a multicenter clinical trial evaluating the safety and efficacy of teclistamab in adults with RRMM.

The metabolic protein SIRT3 reduces the pools of amino acids that cells use to make proteins and otherwise fuel their growth.

Rivaroxaban is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, for the treatment of deep vein thrombosis, and pulmonary embolism.

Crestor is indicated for the treatment of patients with primary hyperlipidemia and mixed dyslipidemia.

Abatacept is also approved for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, and moderate to severe polyarticular juvenile idiopathic arthritis for children 2 years of age and older.